s research will be to examine the effect of siRNA in ovarian cancer samples in the lab, and to test the technique on mice. If successful, human trials would follow.
Treatment on cancer patients could come within 10 years, Huang said.
"We hope we will soon be able to apply this new information to improve outcomes, perhaps by developing better diagnostic markers and treatment strategies that may be useful in customizing treatment for ovarian cancer patients," said Huang.